Catheter ablation of atrial fibrillation

Atrial fibrillation is a common arrhythmia associated with significant morbidity including angina, heart failure and stroke. Medical therapy remains suboptimal with significant side effects and toxicities, as well as a high recurrence rate. Catheter ablation or modification of the atrio-ventricular node with pacemaker implantation provides rate control but subjects the patient to the risks of an implantable device and does nothing to reduce the risk of stroke. Pulmonary vein antrum isolation offers a nonpharmacologic means of restoring sinus rhythm, thereby eliminating the morbidity of atrial fibrillation and the need for anti-arrhythmic drugs.     

Catheter ablation of atrial fibrillation: long-term outcomes

The benefits of percutaneous coronary intervention (PCI) can be offset by periprocedural complications such as acute vessel closure and stent thrombosis in the absence of adequate antiplatelet and antithrombotic therapy. Additionally, conditions occurring after 30 days post-PCI, such as in-stent restenosis or late stent thrombosis can occur. Excess antithrombotic therapy, on the other hand, carries a risk of major gastrointestinal or intracranial bleeding as well as vascular access site bleeding complications. In this review, evidence related to the various pharmacological agents for reduction of stent thrombosis available to clinicians during and after PCI will be explored.     

Catheter ablation of atrial fibrillation: long-term outcomes

Atrial fibrillation is the most common arrhythmia faced in clinical practice with a substantial impact on morbidity, mortality, and heathcare expenditures. Patients with atrial fibrillation in which a rhythm control strategy is desired to improve quality of life have had limited options. The discovery of the role of pulmonary vein triggers has led to the development of catheter ablation techniques that have shown promising short-term success rates. Long-term outcomes were until recently, lacking. These results confirm the inherently recurrent nature of atrial fibrillation and the need for multiple procedures to achieve reasonable long-term successful maintenance of sinus rhythm.     

Catheter ablation of atrial flutter in a heart transplant recipient

In the transplanted heart with biatrial anastomosis, atrial flutter is common and is amenable to catheter ablation. Although this arrhythmia is isthmus dependent, the unique atrial architecture with a suture line through the inferior vena cava-tricuspid annulus isthmus makes the substrate atypical. A cardiac transplant recipient with atrial flutter underwent successful catheter ablation. Five weeks after the procedure, the patient died of a myocardial infarction. The autopsy and histological findings are described and correlated with the electroanatomic map obtained during the ablation. Due to the atrial suture lines, atrial flutter following cardiac transplantation is an isthmus dependent arrhythmia with a different arrhythmogenic substrate. The electrical isthmus (atrial tissue from the tricuspid annulus to the suture line) in these hearts is smaller than the anatomic isthmus.     

Radiofrequency catheter ablation of atypical atrial flutter masquerading as atrial fibrillation

A patient with a surgically repaired double outlet right ventricle developed AF 6 months after successful RF catheter ablation of typical atrial flutter. Guided by a 64-electrode basket catheter, the patient's AF was found to be dependent on an atypical atrial flutter circuit rotating around the fossa ovalis. Successful RF catheter ablation was performed by creating a line of conduction block from the superior vena cava to the fossa ovalis.     

Catheter ablation for atrial fibrillation: mechanism-based curative treatment

The considerable cumulative morbidity and mortality burden resulting from atrial fibrillation has prompted renewed efforts to seek curative and widely applicable therapies. Currently used drugs are not only frequently ineffective at eliminating fibrillation, but may actually be life threatening. Extensive surgery involving both atria has shown that atrial fibrillation can be eliminated in most, if not all, patients, but at a significant cost. The recent discovery of the pivotal role that myocardial extensions into the pulmonary veins play in the initiation, and probably also the maintenance, of atrial fibrillation, has provided a relatively limited target conducive to catheter-based interventions. In experienced hands, paroxysmal atrial fibrillation can be eliminated in more than 85% of patients by a percutaneous intervention lasting less than 3 h with an attendant nonlethal complication risk of 1 to 2%. Thromboembolic complications and pulmonary vein stenosis are the principal complications that may result from this treatment, but their incidence is decreasing. Success rates in patients with persistent or permanent atrial fibrillation are lower, and it is anticipated that increased understanding of the underlying mechanisms will allow doctors to identify those subsets with the greatest potential for benefit from percutaneous catheter-based interventions. Such progress may allow doctors to extend the benefits of eliminating atrial fibrillation to the widest possible range of patients with this recalcitrant disorder.     

Catheter ablation for atrial fibrillation: mechanism-based curative treatment

The considerable cumulative morbidity and mortality burden resulting from atrial fibrillation has prompted renewed efforts to seek curative and widely applicable therapies. Currently used drugs are not only frequently ineffective at eliminating fibrillation, but may actually be life threatening. Extensive surgery involving both atria has shown that atrial fibrillation can be eliminated in most, if not all, patients, but at a significant cost. The recent discovery of the pivotal role that myocardial extensions into the pulmonary veins play in the initiation, and probably also the maintenance, of atrial fibrillation, has provided a relatively limited target conducive to catheter-based interventions. In experienced hands, paroxysmal atrial fibrillation can be eliminated in more than 85% of patients by a percutaneous intervention lasting less than 3 h with an attendant nonlethal complication risk of 1 to 2%. Thromboembolic complications and pulmonary vein stenosis are the principal complications that may result from this treatment, but their incidence is decreasing. Success rates in patients with persistent or permanent atrial fibrillation are lower, and it is anticipated that increased understanding of the underlying mechanisms will allow doctors to identify those subsets with the greatest potential for benefit from percutaneous catheter-based interventions. Such progress may allow doctors to extend the benefits of eliminating atrial fibrillation to the widest possible range of patients with this recalcitrant disorder.     

Catheter ablation of atrial fibrillation with a novel,duty-cycled ablation system

Atrial fibrillation (AF) is the most common arrhythmia experienced in clinical practice (approx. 1% predominance in the adult population). Unfortunately, long-term efficacy of antiarrhythmic drug therapy is disappointing and could cause serious side effects. Radiofrequency (RF) catheter ablation has emerged as an important therapeutic option for drug refractory patients. However, the development in ablation strategies remains complex with often lengthy procedures. This study investigates whether a novel multielectrode catheter, delivering duty-cycled bipolar/unipolar RF energy, is feasible and safe. Therefore, 81 consecutive patients with paroxysmal or persistent AF has been analyzed. Pulmonary vein isolation with the pulmonary vein ablation catheter was safe with short fluoroscopy/procedural time and good clinical efficacy at 6 months (stable sinus rhythm in 78% of patients).     

Severe left ventricular systolic dysfunction increases atrial fibrillation after ablation of atrial flutter

Background: Atrial fibrillation (Afib) that occurs after a successful atrial flutter (AFL) ablation may negate the potential benefits of the ablation. Afib occurs more often when severe left ventricular systolic dysfunction (LVSD) is present. We hypothesized that even after a successful AFL ablation, the incidence of postablation Afib is increased when severe LVSD is present.
Methods: Ninety consecutive patients with LVSD who underwent ablation for AFL at Montefiore Medical Center from August 2001 to January 2005 were classified according to the severity of LVSD. Group 1 (n = 36) consisted of patients with EF ≤ 35%, and group 2 (n = 54) consisted of patients with EF 36–55%. There were no statistically significant differences in baseline patient characteristics between the two groups.
Results: During a mean follow up of 350 days, Afib occurred in 31% (n = 11; 8 with prior history of AFib) in group 1, and 7.4% (n = 4; all with prior history of Afib) in group 2. Cumulative probability of remaining Afib-free in group 1 versus group 2 was 75% versus 96% at 365 days, and 69% versus 91% at 600 days (P = 0.01). A prior history of Afib did not interact with EF when analyzed with a logistic regression analysis.
Conclusion: After an AFL ablation, the incidence of Afib is increased, and the probability of remaining free of Afib is decreased, when severe LVSD is present, independent of a prior history of Afib. This finding may have implications for optimal patient selection for AFL ablation, and the use of adjunctive therapies.     

Catheter ablation of persistent and permanent atrial fibrillation: Bordeaux experience

The seminal observation that ectopics from the pulmonary veins may initiate paroxysmal atrial fibrillation (AF) heralded an era of potentially curative catheter ablation therapy for AF. In recent years, catheter ablation has been performed for not only paroxysmal but also persistent and permanent AF. It is anticipated that the number of procedures will continue to increase and the indication for catheter ablation will expand. This article details our experience with catheter ablation therapy for patients with persistent and chronic AF.     

Catheter ablation of persistent and permanent atrial fibrillation: Bordeaux experience

The seminal observation that ectopics from the pulmonary veins may initiate paroxysmal atrial fibrillation (AF) heralded an era of potentially curative catheter ablation therapy for AF. In recent years, catheter ablation has been performed for not only paroxysmal but also persistent and permanent AF. It is anticipated that the number of procedures will continue to increase and the indication for catheter ablation will expand. This article details our experience with catheter ablation therapy for patients with persistent and chronic AF.     

Catheter ablation for atrial fibrillation: current patient selection and outcomes

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Ablation is an excellent treatment option for appropriately selected patients. Catheter ablation tools and techniques have evolved since AF ablation was first introduced, but pulmonary vein isolation remains the cornerstone of the procedure. Outcomes from ablation have improved dramatically over the last 20 years, but remain less than optimal for certain patient groups.

Areas covered: This review outlines the process of patient selection for AF ablation in contemporary practice, from diagnosis and AF classification to procedural risk assessment. Current guideline indications for AF ablation are reviewed. We discuss current reported outcomes from AF ablation and predictors for arrhythmia recurrence after ablation. The evolution of AF ablation technology and change in patient selection patterns are also discussed.

Expert commentary: AF ablation is an attractive alternative to antiarrhythmic drug therapy for many patients. Patient selection for ablation is an important part of management. Careful patient selection requires thorough, individualized clinical assessment based on symptoms, alternative treatment options, an estimation of procedural risk, and predicted recurrence rate to allow the patient to participate in shared decision-making.     

Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter

The aim of this prospective study was to compare the long-term follow-up after transisthmic ablation of patients with preablation lone atrial flutter, coexistent AF, and drug induced atrial flutter to determine if postablation AF followed a different clinical course and displayed different predictors in these groups. The study evaluated 357 patients who underwent transisthmic ablation for typical atrial flutter. These were divided into four groups according to their preablation history. Group A included patients with typical atrial flutter and without preablation AF (n=120, 33.6%). Group B included patients with preablation AF and spontaneous atrial flutter (n=132, 37.0%). Group C patients had preablation AF and atrial flutter induced by treatment with IC drugs (propafenone or flecainide) (n=63, 17.6%) Group D included patients with preablation AF and atrial flutter induced by treatment with amiodarone (n=42, 11.8%). During a mean follow-up of 15.2 double dagger 10.6 months (range 6-55 months) AF occurred more frequently in groups B (56.1%) and C (57.1%) patients than in groups A (20.8%, P <0.0001) and D (31.0%, P <0.0001) patients. The results of multivariate analysis revealed that different clinical and echocardiographical variables were correlated with postablation AF occurrence in the different groups. Patients with atrial flutter induced by amiodarone have a significantly lower risk of postablation AF than patients with spontaneous atrial flutter and AF, and those with atrial flutter induced by IC drugs. Different clinical and echocardiographical variables predict postablation AF occurrence in different subgroups of patients.     

Management of atrial fibrillation and flutter

Digitalis has long been used as an antiarrhythmic drug in treatment of paroxysmal supraventricular tachycardia, atrial fibrillation and flutter, and arrhythmias associated with congestive heart failure. However, newer evidence indicates that this cardiac glycoside has limited potency as an antiarrhythmic drug. In this review, the authors describe the effect of digitalis on cardiovascular function in management of atrial fibrillation and flutter. They conclude that while widespread use of digitalis as initial treatment for these supraventricular arrhythmias is justified by its low cost, ease of administration, and relatively few noncardiac side effects, newer drugs may ultimately prove more useful.     

Microwave ablation of atrial flutter

Radiofrequency (RF) ablation of the isthmus between the inferior vena cava and the tricuspid ring has proven to be a safe and successful method of treating atrial flutter (AF). However, RF ablation lesions are small in size requiring a considerable number of energy applications to ablate the AF circuit. The aim of this study was to evaluate the feasibility and efficacy of microwave energy for AF ablation. We report a case of sustained typical AF treated successfully and safely by 1 pulse of microwave (MW) energy. This showed it is possible to treat AF with a small number of pulse applications.     

Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation

Atrial fibrillation (AF) is a common clinical problem that is associated with an impaired quality of life, thromboembolism, heart failure and death. Medical treatment of AF remains suboptimal and is associated with potentially serious side effects. The disappointing outcomes with medical therapy have spurred the age of catheter ablation of AF. In the last 10 years, catheter ablation of AF has evolved dramatically and has been shown to be superior to medical therapy in multiple studies. As a result, catheter ablation may be offered to the symptomatic patient as first-line therapy in lieu of antiarrhythmic medications, which have limited efficacy and are associated with significant toxicity.